Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients

[1]  N. Sobhani,et al.  The prognostic value of PI3K mutational status in breast cancer: A meta‐analysis , 2018, Journal of cellular biochemistry.

[2]  N. Magné,et al.  Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Norikazu Masuda,et al.  Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[4]  F. Q. Ribeiro.  The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[5]  Xu Xiaoli,et al.  Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes , 2017, Journal of Clinical Pathology.

[6]  A. Garg,et al.  Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Angela N. Brooks,et al.  High-throughput Phenotyping of Lung Cancer Somatic Mutations. , 2016, Cancer cell.

[8]  G. Hampton,et al.  The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population , 2016, npj Breast Cancer.

[9]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[10]  Ken Chen,et al.  Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. , 2015, Cancer research.

[11]  Aiko Sueta,et al.  Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer , 2015, Cancer science.

[12]  Sandra B Gabelli,et al.  Oncogenic mutations weaken the interactions that stabilize the p110α‐p85α heterodimer in phosphatidylinositol 3‐kinase α , 2015, The FEBS journal.

[13]  R. Bernards,et al.  PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Neville E. Sanjana,et al.  High-throughput functional genomics using CRISPR–Cas9 , 2015, Nature Reviews Genetics.

[15]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[16]  A. Eisen,et al.  Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. , 2015, Current oncology.

[17]  A. Eisen,et al.  Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. , 2014, Current oncology.

[18]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[19]  Obi L. Griffith,et al.  Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.

[20]  J. Baselga,et al.  Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Engelman,et al.  The double life of p85. , 2014, Cancer cell.

[22]  Yiling Lu,et al.  Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. , 2014, Cancer cell.

[23]  Carsten Denkert,et al.  PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Zoe Cournia,et al.  Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant , 2014, PLoS Comput. Biol..

[25]  D. Rea,et al.  Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Arteaga,et al.  PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Bing-he Xu,et al.  Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone , 2014, Breast Cancer Research.

[28]  J. Lehár,et al.  CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. , 2014, Cancer cell.

[29]  Wanqing Chen,et al.  Breast cancer in China. , 2014, The Lancet. Oncology.

[30]  W. Pao,et al.  Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling , 2014, Breast Cancer Research and Treatment.

[31]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[32]  P. V. van Diest,et al.  PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients , 2014, Breast Cancer Research.

[33]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[34]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[35]  Jean J. Zhao,et al.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.

[36]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  C. Perou,et al.  Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies , 2013, Proceedings of the National Academy of Sciences.

[38]  C. Sotiriou,et al.  Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer , 2013, Journal of the National Cancer Institute.

[39]  J. Stockman,et al.  A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome , 2013 .

[40]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[41]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[42]  A. Ashworth,et al.  The promise of combining inhibition of PI3K and PARP as cancer therapy. , 2012, Cancer discovery.

[43]  H. Swerdlow,et al.  A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers , 2012, BMC Genomics.

[44]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[45]  Xin Hu,et al.  Rap80 Protein Recruitment to DNA Double-strand Breaks Requires Binding to Both Small Ubiquitin-like Modifier (SUMO) and Ubiquitin Conjugates* , 2012, The Journal of Biological Chemistry.

[46]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[47]  P. Hawkins,et al.  PI3K signalling: the path to discovery and understanding , 2012, Nature Reviews Molecular Cell Biology.

[48]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  W. Sellers,et al.  Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.

[50]  G. Mills,et al.  High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. , 2011, Cancer discovery.

[51]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  G. Mills,et al.  Oncogenic PIK 3 CA-driven mammary tumors frequently recur via PI 3 K pathway – dependent and PI 3 K pathway – independent mechanisms , 2011 .

[53]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[54]  J. Barrett,et al.  PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer , 2010, Clinical Cancer Research.

[55]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[56]  M. D. Chamberlain,et al.  Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase , 2010, Proceedings of the National Academy of Sciences.

[57]  B. Peters,et al.  Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. , 2009, Cancer cell.

[58]  W. Gerald,et al.  PIK3CA Mutation Associates with Improved Outcome in Breast Cancer , 2009, Clinical Cancer Research.

[59]  S. Johnston,et al.  A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer , 2009, British Journal of Cancer.

[60]  L. Fan,et al.  Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China , 2009, Breast Cancer Research and Treatment.

[61]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[62]  K. Shokat,et al.  PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. , 2008, Cancer research.

[63]  Li Zhao,et al.  Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms , 2008, Proceedings of the National Academy of Sciences.

[64]  Stephen J. Elledge,et al.  Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening , 2008, Science.

[65]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[66]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[67]  C. Lavebratt,et al.  Single nucleotide polymorphism (SNP) allele frequency estimation in DNA pools using Pyrosequencing™ , 2006, Nature Protocols.

[68]  Bert Vogelstein,et al.  The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. , 2007, Science.

[69]  René Bernards,et al.  shRNA libraries and their use in cancer genetics , 2006, Nature Methods.

[70]  P. Vogt,et al.  Cancer-specific mutations in PIK3CA are oncogenic in vivo , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Loda,et al.  The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .

[72]  J. Engelman,et al.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.

[73]  Zhao Chen,et al.  Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.

[74]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[75]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[76]  M. Loda,et al.  The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[77]  J. Debnath,et al.  Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner , 2003, The Journal of cell biology.

[78]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[79]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.